ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer

Gao,Zhiqiang; Han,Baohui; Shen,Jie; Gu,Aiqin; Qi,Dajiang; Huang,Jinsu; Shi,Chunlei; Xiong,Liwen; Zhao,Yizhuo; Jiang,Liyan; Wang,Huimin; Chen,Yurong

doi:10.3892/etm.2011.276

September-October 2011 Volume 2 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-October 2011 Volume 2 Issue 5

Full Size Image

Article

ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer

Authors:
- Zhiqiang Gao
- Baohui Han
- Jie Shen
- Aiqin Gu
- Dajiang Qi
- Jinsu Huang
- Chunlei Shi
- Liwen Xiong
- Yizhuo Zhao
- Liyan Jiang
- Huimin Wang
- Yurong Chen
View Affiliations / Copyright

Affiliations: Department of Pulmonary Medicine, Chest Hospital Affiliated with Shanghai Jiao Tong University, Shanghai 200030, P.R. China
Pages: 811-815
|
Published online on: May 30, 2011

https://doi.org/10.3892/etm.2011.276
Expand metrics +

Abstract

Excision repair cross-complementation group 1 (ERCC1) protein has been associated with cisplatin resistance. The objective of this study was to investigate the correlation between ERCC1 protein levels and the therapeutic effect of individualized therapy in advanced non-small cell lung cancer (NSCLC). A total of 190 advanced NSCLC patients were included in this study. Patients were randomized into either the individualized therapy group or the standard therapy group at a ratio of 2:1. Patients in the standard therapy group were treated with either gemcitabine plus cisplatin or vinorelbine plus cisplatin. The expression of ERCC1 protein in lung cancer tissues of patients from the individualized therapy group was detected with immunohistochemistry. Patients with low ERCC1 levels received either gemcitabine plus cisplatin or vinorelbine plus cisplatin, and patients with high levels received gemcitabine plus vinorelbine. The main outcome assessments were response rate (RR), overall survival (OS) and time to progression (TTP). Follow-up data were recorded until September 30, 2010. RR, 1-year survival rate and TTP were not statistically significant. The median survival time was 10.10 months in the standard therapy group (95% CI 8.48‑11.92) and 13.59 months in the individualized therapy group (95% CI 11.86-14.74). The difference in median survival time was significantly different between these groups (P=0.036). The median survival time was longer in the individualized group compared to the standard therapy group. ERCC1 protein expression in advanced NSCLC patients, however, was not significantly correlated with RR, OS and TTP in the individualized therapy group. Therefore, this study suggests that ERCC1 protein levels should be assessed in combination with additional biomarkers to determine an optimal index for individualized therapy in advanced NSCLC patients.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2.	Aggarwal C, Somaiah N and Simon GR: Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw. 8:822–832. 2010.PubMed/NCBI
3.	Perez-Soler R: Individualized therapy in non-small cell lung cancer: future versus current clinical practice. Oncogene. 28(Suppl 1): 38–45. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Arora A, Siddiqui IA and Shukla Y: Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol Cancer Ther. 3:1459–1466. 2004.
5.	Adams VR and Harvey RD: Histological and genetic markers for non-small cell lung cancer: customizing treatment based on individual tumor biology. Am J Health Syst Pharm. 67:S3–S9. 2010. View Article : Google Scholar : PubMed/NCBI
6.	De Laat WL, Jaspers NG and Hoeijmakers JH: Molecular mechanism of nucleotide excision repair. Genes Dev. 13:768–785. 1999.PubMed/NCBI
7.	Monzo M, Rosell R and Taron M: Drug resistance in non-small cell lung cancer. Lung Cancer. 34(Suppl 2): 91–94. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 17:1818–1825. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Simon G, Sharma A, Li X, et al: Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small cell lung cancer. J Clin Oncol. 25:2741–2746. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 27:5808–5815. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles